Differentiated Care for Improved Health Systems Efficiency and Health Outcomes in Zambia

HIV Clinical Trial

— CommART  

Official title:

Community ART for Retention in Zambia: Evaluating the Feasibility, Effectiveness, and Efficiency of Decentralized and Streamlined Antiretroviral Therapy Care Models

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02776254
• Other study ID #: ID OPP1105306
• Status: Completed
• Phase: N/A
• Start date: March 2016
• Est. completion date: July 2017

Study information

• Verified date: February 2019
• Source: Centre for Infectious Disease Research in Zambia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study seeks to create generalizable knowledge about the implementation process as well as the effectiveness and efficiency of a differentiated care system, by measuring patient health outcomes and implementation outcomes such as acceptability, feasibility, fidelity, and costs

Description:

This is a joint endeavor of the Zambian Ministry of Health (MoH), Ministry of Community Development, Mother & Child Health (MCDMCH) and the Centre for Infectious Disease Research in Zambia (CIDRZ) with funding from the Bill & Melinda Gates Foundation.

The study evaluates four models of streamlined HIV care in reducing patients' time and cost:

(1) community adherence groups (CAG), (2) urban adherence groups (UAG), (3) Fast-Track clinic visits and (4) streamlined ART initiation (START). CAG and UAG are assessed using a cluster-randomized design; Fast-Track and START using an observational approach to compare changes in the outcome through a difference in difference approach.

1. Specific Objectives

Objective 1:

To determine acceptability, appropriateness, and feasibility of a differentiated care system in Zambia, by assessing perspectives of (1) patients and family members (2) health care workers and (3) government and local leaders.

Objective 2:

To evaluate effectiveness (retention), efficiency (cost-effectiveness), and health care quality (quantitative and qualitative measures) of a differentiated and targeted care system.

Objective 3:

To develop a "methodologic" toolkit for assessment of local needs, preferences and scale-up of differentiated care models in varied contexts, using data from Objectives 1 and 2.

2.0 Methodology 2.1 Objective 1 Mixed methods approach will be used to evaluate perceptions on challenges in accessing and adhering to life-long HIV treatment and to assess needs/preferences for differentiated care models collected from patients and family members (demand side), health facilities -professional and community health workers (supply side), and government and local leaders using in-depth interviews (IDIs), focus group discussions (FGDs), and discrete choice surveys (DCS) to sequentially analyze supply and demand side factors that may influence uptake.

Population Key government and other stakeholders in HIV or other relevant community based service delivery will be interviewed. Professional and lay health workers in ART program, Pre-ART and ART patients and, a sample of household members of ART or pre-ART patient registered at selected health facility will be interviewed.

Measurements/Procedures For Objective 1: IDIs, FGDs, medical chart reviews, DCS/general survey Semi-structured guides by participant type will be used to conduct IDIs and FGDs in English or a local language (Nyanja, Bemba, or Tonga). Where permitted, IDIs/FGDs will be audio-recorded for transcription and analysis. Participants will be reimbursed for travel. IDIs will last 1 and FGDs 1-2 hours.

A cross-sectional survey will be used to measure patient access and psychosocial needs. Access needs will be assessed by questions on appropriateness of current clinic operating hours; distance, cost, and time to reach clinic; household income, assets, and expenditures; and opportunity costs of a clinic visit. Patient costs related to health care utilization, including transport, communication, and food costs will be elicited. To assess psychosocial needs, validated scales and indices to measure stigma (Revised Berger), depression (PHQ-9), alcohol consumption (AUDIT-C), and domestic violence will be applied. The survey administered in the language of participant's choice by trained survey enumerators using tablets will take approximately 30-45 minutes and uploaded to the central database.

The electronic clinical information system (SmartCare) will be utilized to evaluate patient clinical needs. Distribution of clinical needs will be assessed for degree of immunosuppression at entry into care, frequency of opportunistic infections after treatment initiation, and frequency of "ill" versus "healthy" visits.

DCSs will be used to assess patient preference for different, discrete characteristics of various models of community-based ART delivery. All possible combinations of key attributes/aspects of community-based ART models and number of levels/options for them will be put in subsets divided in blocks. Each participant is asked only one possible block of about 10 questions.

Analytic Approach Qualitative data will be imported into software for managing qualitative analysis (e.g. N-Vivo or Atlas TI), iteratively coded and cross-referenced with survey data. Scale scores may be analyzed using descriptive statistics and linear regression modeling. For DCS, main effects plus two-way interactions between different parameters will be estimated using a nested logit framework.

Sampling Approach/Sample Size Considerations The convenience sample consists of 20 IDIs with government and community leaders; two FGDs each with professional HCW, Lay HCW and family members from1 urban and 1 rural clinic in each province; 4 FGDs with ART patients (2 urban and 2 rural clinic) in each province; and 2 FGDs with pre-ART patients (1 urban and 1 rural clinic) in Lusaka province only.

General survey: 1,600 patients (of which 800 are ART and 800 are pre-ART). A precision approach was used to calculate number of ART and pre-ART participants respectively necessary to estimate a binary indicator with 5% margin of error and 95% confidence interval, assuming a prevalence of p=0.5 and a design effect of 2 [ n=((1.96^2) * 0.5* 0.5 *2)/(0.05^2)=768].

2.2 Objective 2: To evaluate the effectiveness, efficiency, and health care quality of a differentiated system of care that includes targeted models of care.

Effectiveness of a differentiated system of HIV care delivery in which frequency, type, or intensity of contact with the health system is tailored to patient needs will be evaluated. CAGs, UAGs, fast-track, and START will be simultaneously implemented and evaluated using a common evaluation framework that includes effectiveness (retention), efficiency, and quality.

Methodology A matched cluster randomized design approach is proposed for CAG and UAG models to account for the clinic-level intervention and possible selection bias. With little to no observational/ implementation data for Fast-Track and START models globally, a difference-in-difference design will be used to calculate effect of the models on outcomes.

Population See inclusion and exclusion criteria Procedures Description of Interventions:

Entered elsewhere

Patient recruitment:

At all intervention sites: Facility staff will identify eligible patients during routine clinic visits and notify the study research assistant about potential study participants. The research study assistant will assess patient willingness to participate in the intervention and will obtain informed consent for study participation.

START model: Staff will use national guidelines to determine ART eligibility and, with participants' informed consent, expedite provision of on-site CD4 testing using point of care platform for all newly diagnosed and ART-naive patients due for routine CD4 monitoring. Participants will not be actively followed in the 12-months after ART initiation.

At control sites: Eligible patients at control sites, willing to join CAG and UAG studies, will be enrolled. Consent will be obtained to extract their SmartCare data.

Baseline viral load testing:

For participants enrolled into CAG, UAG and Fast-Track intervention, dry blood spot specimens will be obtained via finger prick. Specimens will be transmitted to CIDRZ central laboratory for baseline viral load testing. Results will be communicated to providers and patients and, documented in SmartCare.

Costing A subset of participants in each model will be interviewed on direct and indirect health costs of the intervention using a semi-structured questionnaire. Administrative data may also be used.

Exit viral load testing and patient exit-survey All participants will have an exit viral load test in the 12th month. In CAG, UAG, and Fast-Track models, a patient exit-survey will assess patient satisfaction and patient centeredness.

Measurements Standard de-identified socio-demographic, laboratory and clinical data will be extracted from SmartCare.

Information in model-specific registers (attendance, receipt of medications, symptom checklist, patient preference between intervention and standard care, up-referral due to presence of symptoms or a patient's desire to return to standard care, or down-referral to model when patients with acute illness stabilize) will be entered into the study database using a tablet.

Patient satisfaction and centeredness will be captured by the semi-structured patient-exit survey conducted after the 12-month intervention period.

Baseline and exit viral load testing will be conducted. A semi-structured costing questionnaire used with a subset of intervention participants will assess related direct and indirect health costs. To calculate resource use of each activity, time-in-motion studies will be conducted among patients and health care workers prior to and during the intervention.

Process data will be collected facility-level assessments of pharmacy stock outs and through HCW interviews at end of follow-up period.

Analytic Approach For START, date of ART initiation is the primary outcome. For CAG and UAG interventions, Kaplan-Meier estimates of time to the primary outcome, stratified by intervention condition, using log rank tests will be calculated. For Fast-track and START, primary analysis will take a difference-in-difference approach to estimate difference in the change in the rate of the outcome in intervention settings. In secondary analyses of the primary outcome, longer intervals of lateness that comprise a missed pharmacy visit (14 and 30 days) as well as adjustment for baseline patient characteristics will be explored along with analysis using medication possession ratio (MPR) as the outcome and other metrics of retention that incorporate both frequency of missed visit and interval of time before return.

Sample Size Considerations CAG/UAG: Program data suggest that 65% of patients are > 7 days late for a pharmacy refill visit in their first year of ART in 95% (+15%) of clinics. Assuming a conservative matched co-efficient of variation of 0.10 and a 50% reduction in missed pharmacy visits, selection of five clinics and 90 patients per site will yield power of 96% for CAG intervention. Under more conservative assumptions about between clinic variability and the effect size, this sample size yields >80% power. For UAG intervention, target sample size is 4 UAGs of 30 people each in five intervention sites (120 participants per site; 600 across sites). Under the same assumptions as the CAG model, this sample size yields power of > 90% and is robust to varying assumptions about correlation.

Fast-track: Targeting 200 patients at each of four sites (2 intervention and 2 control sites), a fall to 40% of the assumed 80% patients that miss a pharmacy visit in the first year, gives 80% power.

START: Assuming ART initiation at 2 weeks rises from 60% to 85%, 100 patients at each of eight sites (4 intervention and 4 control sites; n=800), rho of 0.15 yields an anticipated power of 78%.

2.3 Objective 3: Methodological Toolkit After data synthesis, a methodological toolkit will be developed to guide assessment of feasibility, acceptability, needs, preferences and implementation for differentiated care models. Data will be collected using work process tracking and costing; and interviews with study staff and key decision makers. The toolkit will be easily digestible and lead to actionable plans to move from current to differentiated care models in differing circumstances and contexts. With input from reviewers, the toolkit will be finalized and digital and hard copies will be distributed at dissemination events with the MoH, MCDMCH and other national and sub-national stakeholders.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3100
• Est. completion date: July 2017
• Est. primary completion date: July 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 15 Years and older

Eligibility

Inclusion Criteria:

• HIV-positive adolescents and adults (> 14 years of age)

• Last CD4 count (obtained within the last six months) > 200

• Not acutely ill

• For CAGs, UAGs, and Fast-Track models: on ART for at least 6 months

• For the START model: ART naïve and meet the Zambian HIV guidelines for treatment initiation

Exclusion Criteria:

• For CAGs, UAGs: Inability to participate in the group activities due to cognition deficits or mental illness.

• Unable to provide consent or unwilling to participate in study

• Pregnancy

Related Conditions & MeSH terms

• HIV

Intervention

Other:
• START
Point of care testing for rapid ART initiation
• CAG
Community Adherence Group
• UAG
Urban Adherence Group
• FAST-TRACK
Prescription refill only

Locations

Country	Name	City	State
Zambia	Centre for Infectious Disease Research in Zambia	Lusaka

Sponsors (8)

Lead Sponsor	Collaborator
Centre for Infectious Disease Research in Zambia	American Institutes for Research, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Ministry of Health, Zambia, University of Alabama at Birmingham, University of California, San Francisco, University of Zambia

Country where clinical trial is conducted

Zambia, 

References & Publications (16)

Babigumira JB, Castelnuovo B, Stergachis A, Kiragga A, Shaefer P, Lamorde M, Kambugu A, Muwanga A, Garrison LP. Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS One. 2011 Mar 28;6(3):e18193. doi: 10.1371/journal.pone.0018193. — View Citation

Bemelmans M, Baert S, Goemaere E, Wilkinson L, Vandendyck M, van Cutsem G, Silva C, Perry S, Szumilin E, Gerstenhaber R, Kalenga L, Biot M, Ford N. Community-supported models of care for people on HIV treatment in sub-Saharan Africa. Trop Med Int Health. 2014 Aug;19(8):968-77. doi: 10.1111/tmi.12332. Epub 2014 May 28. — View Citation

Brennan AT, Long L, Maskew M, Sanne I, Jaffray I, MacPhail P, Fox MP. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011 Oct 23;25(16):2027-36. doi: 10.1097/QAD.0b013e32834b6480. — View Citation

Decroo T, Koole O, Remartinez D, dos Santos N, Dezembro S, Jofrisse M, Rasschaert F, Biot M, Laga M. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health. 2014 May;19(5):514-21. doi: 10.1111/tmi.12278. Epub 2014 Feb 12. — View Citation

Decroo T, Telfer B, Biot M, Maïkéré J, Dezembro S, Cumba LI, das Dores C, Chu K, Ford N. Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):e39-44. doi: 10.1097/QAI.0b013e3182055138. — View Citation

Fairall L, Bachmann MO, Lombard C, Timmerman V, Uebel K, Zwarenstein M, Boulle A, Georgeu D, Colvin CJ, Lewin S, Faris G, Cornick R, Draper B, Tshabalala M, Kotze E, van Vuuren C, Steyn D, Chapman R, Bateman E. Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial. Lancet. 2012 Sep 8;380(9845):889-98. doi: 10.1016/S0140-6736(12)60730-2. Epub 2012 Aug 15. — View Citation

Health ZMo. UNAIDS Country Progress Report Zambia. March 31, 2012 2012.

Hickey MD, Salmen CR, Omollo D, Mattah B, Fiorella KJ, Geng EH, Bacchetti P, Blat C, Ouma GB, Zoughbie D, Tessler RA, Salmen MR, Campbell H, Gandhi M, Shade S, Njoroge B, Bukusi EA, Cohen CR. Implementation and Operational Research: Pulling the Network Together: Quasiexperimental Trial of a Patient-Defined Support Network Intervention for Promoting Engagement in HIV Care and Medication Adherence on Mfangano Island, Kenya. J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):e127-34. doi: 10.1097/QAI.0000000000000664. — View Citation

Humphreys CP, Wright J, Walley J, Mamvura CT, Bailey KA, Ntshalintshali SN, West RM, Philip A. Nurse led, primary care based antiretroviral treatment versus hospital care: a controlled prospective study in Swaziland. BMC Health Serv Res. 2010 Aug 5;10:229. doi: 10.1186/1472-6963-10-229. — View Citation

Jaffar S, Amuron B, Foster S, Birungi J, Levin J, Namara G, Nabiryo C, Ndembi N, Kyomuhangi R, Opio A, Bunnell R, Tappero JW, Mermin J, Coutinho A, Grosskurth H; Jinja trial team. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet. 2009 Dec 19;374(9707):2080-2089. doi: 10.1016/S0140-6736(09)61674-3. Epub 2009 Nov 24. — View Citation

Kipp W, Konde-Lule J, Saunders LD, Alibhai A, Houston S, Rubaale T, Senthilselvan A, Okech-Ojony J. Antiretroviral treatment for HIV in rural Uganda: two-year treatment outcomes of a prospective health centre/community-based and hospital-based cohort. PLoS One. 2012;7(7):e40902. doi: 10.1371/journal.pone.0040902. Epub 2012 Jul 17. — View Citation

Kredo T, Ford N, Adeniyi FB, Garner P. Decentralising HIV treatment in lower- and middle-income countries. Cochrane Database Syst Rev. 2013 Jun 27;(6):CD009987. doi: 10.1002/14651858.CD009987.pub2. Review. — View Citation

Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M, Mantangana N, Mathee S, Dubula V, Ford N, Hernán MA, Boulle A. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8(2):e56088. doi: 10.1371/journal.pone.0056088. Epub 2013 Feb 13. — View Citation

Rasschaert F, Telfer B, Lessitala F, Decroo T, Remartinez D, Biot M, Candrinho B, Mbofana F, Van Damme W. A qualitative assessment of a community antiretroviral therapy group model in Tete, Mozambique. PLoS One. 2014 Mar 20;9(3):e91544. doi: 10.1371/journal.pone.0091544. eCollection 2014. — View Citation

Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011 Jul;8(7):e1001056. doi: 10.1371/journal.pmed.1001056. Epub 2011 Jul 19. Review. — View Citation

Selke HM, Kimaiyo S, Sidle JE, Vedanthan R, Tierney WM, Shen C, Denski CD, Katschke AR, Wools-Kaloustian K. Task-shifting of antiretroviral delivery from health care workers to persons living with HIV/AIDS: clinical outcomes of a community-based program in Kenya. J Acquir Immune Defic Syndr. 2010 Dec;55(4):483-90. doi: 10.1097/QAI.0b013e3181eb5edb. — View Citation

* Note: There are 16 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retention in care (Time to first missed pharmacy pick-up)	Time to first missed pharmacy pick-up (>7 days)	12 months
Secondary	Feasibility of implementing differentiated care from stakeholder perspectives	stakeholders' perceptions on factors that facilitate or impede delivery of differential models of care through qualitative assessments (i.e. HCW interviews at end of follow-up period).	12 months
Secondary	Feasibility of implementing differentiated care based on ART availability	facility-level assessments (i.e. frequency of pharmacy stock outs) that facilitate or impede delivery of differential models of care	12 months
Secondary	Activity Based Costing (cost per activity based on Time and Motion)	Cost per activity will be estimated using time-in-motion forms among health care workers prior to and during implementation	12 months
Secondary	Cost to patient based on semi-structured interviews	Cost will be estimated through a semi-structured costing questionnaire administered to a subset of intervention participants to assess direct and indirect health costs of the intervention.	12 months
Secondary	Research Costs (cost of conducting implementation science)	Activity-based cost of researching differentiated care based on budgets and spending reports	12 months
Secondary	Fidelity by monitoring the proportion of eligible patients successfully enrolled and retained in a model.	proportion of eligible patients successfully enrolled and retained in a model	12 months
Secondary	Access to care (time in days from positive symptom screen to appropriate referral)	Time (days) from positive symptom screen to appropriate referral	12 months
Secondary	Efficiency (Difference between cost per additional patient retained and the cost per death averted divided by the difference in their effect)	Difference between Incremental cost per additional patient retained and the cost per death averted divided by the difference in their effect	12 months
Secondary	Proportion of patients with appropriate laboratory monitoring (CD4 count testing)	As this is an assessment of models of delivering ART in a manner more efficient than presentation to clinician every month, safety is estimated by appropriate referral based on laboratory monitoring by clinical staff (CD4 count every 6 months for a year)	every 6 months for a year
Secondary	Proportion of patients with appropriate laboratory monitoring through viral load testing	As this is an assessment of models of delivering ART in a manner more efficient than presentation to clinician every month, safety is estimated by appropriate referral based on laboratory monitoring by clinical staff (Viral load every 12 months)	12 months
Secondary	Proportion of patients with appropriate symptom screening	As this is an assessment of models of delivering ART in a manner more efficient than presentation to clinician every month, safety is estimated by appropriate referral based on symptom screening by study staff (every 1-3 months per year)	Every 1-3 months for 12 months
Secondary	Retention rate disaggregated by age (adult and adolescent)	Comparison of retention rates between adults and adolescents will be used as a measure of equity	12 months
Secondary	Retention rate disaggregated by sex (male and female)	Comparison of retention rates between men and women will be used as a measure of equity	12 months
Secondary	Proportion of patients virally suppressed at one year among those exposed to the intervention compared to control conditions using mixed effects logistic regression	Viral suppression should be comparable between the intervention and control groups to ascertain whether patient outcomes are better or at least the same as current routine practice	12 months
Secondary	Patient satisfaction using patient exit-survey	Effect of the intervention on patient satisfaction through mixed effects linear regression	12 months

External Links

•   Frontieres MS. Community ART Group Toolkit: How to Implement the CAG Model. http://www.msf.org/sites/msf.org/files/cag_toolkit.pdf. Accessed August 28, 2014